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Background/aim: Benign multiple sclerosis (BMS) patients display preserved somatic neurological functions but nevertheless may
develop cognitive dysfunction. Our aim was to explore the impact of computer-assisted cognitive rehabilitation (CCR) on cognitive
functions of BMS patients.
Materials and methods: Age- and sex-matched BMS patients (n = 21), non-BMS patients (n = 22), and healthy individuals (n = 38)
were recruited for evaluation of cognitive functions. CCR was administered to 10 BMS patients and a panel of neuropsychological tests
were employed at baseline and 6 months. CCR was based on mental exercise software containing attention, memory, reasoning, visual,
and verbal task modules.
Results: BMS and non-BMS patients showed impaired selective reminding, spatial recall, symbol digit modalities (SDMTs), controlled
oral word association (COWAT), paced auditory serial addition-3 (PASAT-3), and Stroop tests. Timed 25-foot walk and 9-hole peg test
results of BMS patients were comparable to those of healthy controls. BMS patients with CCR showed significantly improved SDMTs,
COWAT, and Stroop test results compared to those without CCR.
Conclusion: Several cognitive domains including memory and executive functions are impaired in BMS patients. CCR has an
ameliorating impact particularly on sustained attention, information processing speed, verbal fluency, categorical reasoning, and
executive functions of BMS patients.
Key words: Benign multiple sclerosis, computer-assisted cognitive rehabilitation, memory, sustained attention, executive functions

1. Introduction
Cognitive impairment is frequently encountered in
multiple sclerosis (MS), affecting up to 70% of patients
(1). Cognitive functions are affected in both late and
early (including clinically isolated syndrome) stages
of the disease and continue deteriorating during the
disease course (2,3). A broad range of cognitive domains
including attention, information processing, learning,
memory, executive functions, and visual-spatial functions
are negatively affected, ultimately causing poor life quality
and reduced participation in social activities (4–6). Several
studies have shown that neuropsychological rehabilitation
may have favorable effects on cognitive functions of MS
patients. There is also accumulating evidence suggesting
that computer-assisted cognitive rehabilitation (CCR)
programs might improve cognitive skills (7).
Although different descriptions of benign MS (BMS)
exist, it is often described as having a relatively lower
Expanded Disability Status Scale (EDSS) score (generally
≤3.0) at a disease duration of 10 or more years (8). Despite

having preserved visual, motor, and sensory functions
(hence low EDSS scores), BMS patients might display
substantial cognitive impairment, which likely occurs
due to damage in the normal appearing white matter of
BMS patients (9). Nevertheless, the impact of cognitive
rehabilitation has never been studied in BMS.
In this study, cognitive and motor functions of age-,
sex-, and disease duration-matched MS patients with and
without benign course were evaluated. Then the influence
of a multidomain CCR program on cognitive functions of
BMS patients was investigated by baseline and follow-up
neuropsychological tests.
2. Materials and methods
2.1. Participants
Twenty-one MS patients with benign disease (EDSS of
≤3.0) more than 10 years after onset were included (8).
MS patients with comparable age/sex and EDSS >3.0 more
than 10 years after disease onset (non-BMS, n = 22) and
healthy individuals (n = 38) were recruited as controls.
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Eight non-BMS patients had secondary progressive MS
(SPMS), whereas the remaining non-BMS patients had
relapsing remitting MS (RRMS). All MS patients fulfilled
the revised McDonald criteria (10). Individuals with severe
visual loss, a history of psychiatric disease or dementia,
alcohol or substance abuse, education of <8 years, previous
cognitive rehabilitation training, a relapse, or steroid
treatment within the 3 months prior to inclusion were
excluded. Disease-modifying (interferon-beta, glatiramer
acetate, or fingolimod) and symptomatic treatments were
continued during the study. All participants signed an
informed consent form and the study was approved by the
institutional review board.
2.2. Neuropsychological assessment
Participants were evaluated by Rao’s Brief Repeatable
Battery of Neuropsychological Tests (BRB-N) before
(baseline) and after (month 6) intervention. The BRB-N
contains subtests that assess MS-specific impairments (11)
such as immediate verbal recall [(Selective Reminding
Test (SRT-IML)], verbal memory acquisition (SRTTL), delayed verbal learning (SRT-DL), immediate
visual recall [10/36 Spatial Recall Test (SPART-IML)],
visual memory acquisition (SPART-TL), delayed visual
learning (SPART-DL), sustained attention and speed of
information processing [Paced Auditory Serial Addition
Test-3 (PASAT-3), Symbol Digit Modalities Test (SDMT)],
and verbal fluency and categorical reasoning [Controlled
Word Association Test (COWAT)]. In addition, the
Stroop Color-Word Test was included to evaluate
executive functions, the Beck Depression Inventory was
administered to evaluate mood, and 9-hole peg and timed
25-foot walk tests were administered to evaluate motor
functions. Results of these tests were expressed as mean
± standard deviation of the BMS, non-BMS, and healthy
control groups, respectively.
2.3. Cognitive intervention
The CCR)was based on the NOROSOFT Mental Exercise
Program. NOROSOFT contains five modules: attention,
memory, reasoning, visual, and verbal tasks. Patients were
asked to practice 5 days a week for 50 min. The sessions had
20 min of a daily exercise section, which allows patients
to perform every module, and 30 min of impairmentspecific training according to Rao’s BRB-N scores for each
patient. For the weekly follow-up, patients were supervised
by the program’s institutional interface. Each patient was
evaluated by one of the authors on a monthly basis. CCR
was randomly administered to 10 of the 21 BMS patients
on the basis of a computerized list of random numbers.
A psychologist, blind to the study, administered and
evaluated the tests and another psychologist explained
the training procedure and supervised the rehabilitation
program.
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2.4. Statistical analysis
Continuous variables were presented using means and
standard deviations. Demographic and clinical features
of study groups were compared with ANOVA, the chisquare, Student’s t-test, and the Mann–Whitney U test, as
required. Differences between test scores of BMS patients,
non-BMS patients, and healthy controls were assessed by
ANOVA and Tukey’s post hoc test. Differences between
test scores of BMS patients at baseline and the 6th month
were compared with Student’s t-test. The effect of CCR on
the change in test performances over time was investigated
using repeated measures ANOVA. P < 0.05 was inferred as
statistical significance.
3. Results
3.1. BMS patients show impaired cognitive test scores despite preserved motor functions
BMS patients, non-BMS patients, and healthy controls had
comparable age and sex. There were also no differences
between MS duration, disease onset age, relapse numbers,
and BDI scores of BMS and non-BMS patients. EDSS
scores of non-BMS patients (between 3.5 and 6.0) were
significantly higher than those of BMS patients (between
1.5 and 3.0), as expected (Table). To compare motor and
cognitive functions of BMS and non-BMS patients, a
panel of tests were employed for all MS patients. Both
BMS and non-BMS patients had significantly lower SRTIML (5.0 ± 1.4, 4.4 ± 1.3, 6.1 ± 1.5; P < 0.0001), SRT-TL
(7.9 ± 1.5, 7.3 ± 1.3, 9.2 ± 1.3; P < 0.0001), SRT-DL (7.8
± 2.9, 6.7 ± 2.7, 9.7 ± 2.1; P < 0.0001), SPART-TL (4.5 ±
1.5, 4.5 ± 1.5, 6.2 ± 1.4; P < 0.0001), SPART-DL (4.8 ± 2.2,
4.9 ± 2.3, 7.0 ± 2.3; P = 0.0003), PASAT-3 (41.4 ± 13.0,
33.3 ± 9.1, 48.7 ± 7.7; P < 0.0001), SDMT (41.8 ± 15.5,
32.9 ± 15.9, 51.0 ± 12.1; P = 0.0001), and COWAT (60.7
± 19.7, 48.5 ± 18.3, 75.6 ± 17.5; P < 0.0001) scores than
healthy controls. Although non-BMS and BMS patients
showed trends towards reduced SPART-IML (4.3 ± 2.1,
3.9 ± 1.5, 4.8 ± 1.9; P = 0.2177) scores, this difference did
not attain statistical significance. The Stroop test was also
impaired in both non-BMS and BMS patients (47.7 ± 32.4,
65.2 ± 34.2, 36.8 ± 14.7; P = 0.0006). However, since BMS
patients had relatively better Stroop test scores, two-group
comparisons attained significance only among non-BMS
patients and healthy controls (P < 0.001). There were no
significant differences among cognitive test scores of nonBMS and BMS patients, with the exception of PASAT-3
scores, which were relatively improved in BMS patients (P
< 0.05). While 9-hole peg (20.1 ± 1.9, 27.8 ± 11.2, 18.6 ±
2.1; P < 0.0001) and timed 25-foot walk tests (6.7 ± 1.1, 9.2
± 3.7, 6.1 ± 1.5; P < 0.0001) were impaired in non-BMS
patients, BMS patients showed scores comparable to those
of healthy controls (Figure 1).
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Table. Clinical and demographic features of benign MS (BMS) patients, non-BMS patients, and healthy
controls (HC).
BMS
(n = 21)

non-BMS
(n = 22)

HC
(n = 38)

P

Sex (F/M)

15/6

12/10

28/10

0.286*

Age, years (SD)

37.0 (7.6)

39.3 (9.0)

36.0 (10.2)

0.355**

Age of MS onset, years (SD)

23.7 (6.9)

27.4 (9.0)

-

0.147***

Duration of MS, years (SD)

13.2 (4.2)

14.8 (5.7)

-

0.327***

EDSS, mean (SD)

2.2 (0.5)

4.2 (0.8)

-

<0.001†

Number of relapses, mean (SD)

7.7 (3.8)

7.5 (4.3)

-

0.889***

BDI scores, mean (SD)

7.9 (4.7)

11.1 (8.5)

7.0 (5.7)

0.144***

F, Female; M, male; SD, standard deviation; EDSS, Expanded Disability Status Scale; BDI, Beck Depression
Inventory. *, Chi-square; **, ANOVA; ***, Student’s t-test; †, Mann–Whitney U test.

3.2. CCR ameliorates cognitive functions in BMS
To evaluate the impact of CCR on cognitive functions of
BMS patients, cognitive test scores of BMS patients with (n
= 10) and without (n = 11) CCR were evaluated before and
6 months after initiation of CCR. When scores before and
after CCR were compared with Student’s t-test, in the BMS
group without CCR, SDMT (before 42.1 ± 14.1 vs. after 36.0
± 10.7; P = 0.031) and Stroop (before 47.7 ± 37.6 vs. after
63.7 ± 49.3; P = 0.043) test scores significantly deteriorated.
Alternatively, in the BMS group with CCR, after 6 months
of treatment, BMS patients showed significantly improved
PASAT-3 scores (before 40.3 ± 12.8 vs. after 46.3 ± 11.3; P
= 0.008). Other cognitive and motor test scores remained
relatively identical. When all four groups with and without
CCR were compared with repeated measures ANOVA,
CCR was found to exert a positive influence on SDMT (P
= 0.016), COWAT (P = 0.036), and Stroop (P = 0.023) test
scores (Figure 2).
4. Discussion
Memory, attention, and frontal lobe cognitive domains
of BMS patients are well known to be impaired (12).
Moreover, BMS and non-BMS patients show identical
cognitive impairment frequency and cognitive
deterioration pace (13). Deficits in executive functions,
processing speed, and attention have been associated with
structural damage of tracts connecting the cortical and
subcortical regions of the brain (14). Similar to previous
reports, in our study, BMS patients displayed deficits in
a wide range of cognitive functions including verbal and
visual memory, attention, and executive functions and,
as a result, BMS and non-BMS patients showed similar
neuropsychological profiles. By contrast, 9-hole peg and
timed 25-foot walk tests were not impaired in non-BMS
patients, indicating preserved motor functions in this

MS subgroup. Thus, our results confirm the notion that
regions of the brain associated with cognitive functions
are affected in BMS, while those associated with somatic
neurological functions are relatively preserved. Notably,
while displaying equally impaired scores as non-BMS
patients in most cognitive tests, BMS patients’ Stroop and
PASAT-3 test performances were relatively better than
those of non-BMS patients. This might be due to the fact
that BMS patients have increased activation of the cognitive
network regions involved in executive functions owing to
adaptive functional cortical changes (15). To establish a
comparable patient control group, non-BMS patients were
selected from among MS patients with disease duration
of more than 10 years and thus some non-BMS patients
were inadvertently in the progressive stage of MS. In future
studies, it might be advisable to establish a homogeneous
non-BMS control group comprising only RRMS patients.
Response of these intermediate RRMS patients (neither
BMS nor SPMS despite >10 years of disease duration) to
CCR is also worth investigating.
CCR has been widely used for rehabilitation of the
cognitive dysfunction of MS patients, improving scores
obtained in a broad range of neuropsychological tests
(16–18). To our knowledge, our study has shown for the
first time that BMS patients also benefit from CCR. The
amelioration in PASAT-3, SDMT, COWAT, and Stroop
test scores was more pronounced than that observed for
verbal and visual memory test scores. Notably, SDMT and
Stroop test scores showed trends towards deteriorating in
nonrehabilitated BMS patients in a 6-month time span.
In CCR-administered patients this deterioration pattern
appears to have been reversed, leading to either unaffected
or significantly improved test scores. Similar CCR-induced
improvements of PASAT and Stroop test scores have been
previously shown in non-BMS patients, as well (16–20). It
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Figure 1. Neuropsychological test results of benign MS (BMS) patients, non-BMS patients, and healthy controls (HC). Horizontal lines
indicate mean values. P-values for three-group comparisons (by ANOVA) are indicated at the lower left corner of each panel. Significant
two-group comparisons (by Tukey’s post hoc test) are denoted at the top of the panels. *, P < 0.05; **, P < 0.01; ***, P < 0.001. IML,
Immediate learning; DL, delayed learning; TL, total learning.
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Figure 2. Neuropsychological test results of benign MS patients with (w) and without (wo) computer-assisted cognitive rehabilitation
(CCR). P-values for four-group comparisons (by repeated measures ANOVA) are indicated at the lower left corner of each panel. IML,
Immediate learning; DL, delayed learning; TL, total learning.
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should be noted as a limitation that the tool administered
in CCR has similar features with the assessment tools and
therefore some of the observed benefits of CCR after 6
months of training could be at least partly due to learning
effects.
PASAT-3, SDMT, COWAT, and Stroop tests assess
sustained attention, information processing speed,
verbal fluency, and categorical reasoning, all of which
are known to be mediated by executive functions (21–
23). The differential amelioration pattern induced by

CCR might be the consequence of the above-mentioned
adaptive enhanced activity of executive function regions
of the brain (15). Alternatively, these regions might have
been less severely afflicted in BMS, providing a cognitive
reserve that enables prompt restoration by rehabilitation
efforts. In conclusion, BMS patients might show severe
cognitive deficits, which may potentially respond to
neuropsychological rehabilitation. The long-term effects of
CCR and the most ideal cognitive rehabilitation methods
for BMS patients need to be further studied.
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